Psychiatry, the pharmaceutical industry, and the road to better therapeutics.
作者信息
Fibiger H Christian
出版信息
Schizophr Bull. 2012 Jun;38(4):649-50. doi: 10.1093/schbul/sbs073.
Abstract
摘要
相似文献
1
Psychiatry, the pharmaceutical industry, and the road to better therapeutics.精神病学、制药行业与通往更好治疗方法之路。
Schizophr Bull. 2012 Jun;38(4):649-50. doi: 10.1093/schbul/sbs073.
2
Co-opting psychiatry: the alliance between academic psychiatry and the pharmaceutical industry.拉拢精神病学：学术精神病学与制药行业之间的联盟
Epidemiol Psichiatr Soc. 2007 Jul-Sep;16(3):192-6.
3
[Financial conflict of interest in clinical psychiatry studies: a review].[临床精神病学研究中的财务利益冲突：综述]
Turk Psikiyatri Derg. 2008 Winter;19(4):418-26.
4
Psychiatric drugs and children.精神科药物与儿童
Science. 2003 May 9;300(5621):901. doi: 10.1126/science.300.5621.901b.
5
The changing nature of psychiatry.
Aust N Z J Psychiatry. 1992 Jun;26(2):323-6. doi: 10.3109/00048679209072049.
6
[Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry].苦涩与镀金的药丸：制药行业影响下的精神病学（处于其影响的光亮或阴影之中）
Tijdschr Psychiatr. 2006;48(2):119-29.
7
Taking a narrative turn in psychiatry.
Lancet. 2014 Jan 4;383(9911):22-3. doi: 10.1016/s0140-6736(13)62722-1.
8
Revitalizing psychiatric drug discovery.重振精神科药物研发。
Nat Rev Drug Discov. 2012 Jun 1;11(6):423-4. doi: 10.1038/nrd3755.
9
The intellectual crisis of psychiatric research.精神病学研究的智力危机。
Psychother Psychosom. 2006;75(4):202-8. doi: 10.1159/000092890.
10
[Personalized medicine in psychiatry -- an old concept from a new aspect].[精神病学中的个性化医疗——新视角下的旧概念]
Neuropsychopharmacol Hung. 2012 Mar;14(1):2-3.
引用本文的文献
1
Study protocol for "MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study".“摇头丸辅助治疗重度抑郁症：一项原理验证研究”的研究方案。
Front Psychiatry. 2022 Oct 26;13:954388. doi: 10.3389/fpsyt.2022.954388. eCollection 2022.
2
Annual Research Review: The contributions of the RDoC research framework on understanding the neurodevelopmental origins, progression and treatment of mental illnesses.年度研究综述：RDoC 研究框架对理解精神疾病的神经发育起源、进展和治疗的贡献。
J Child Psychol Psychiatry. 2022 Apr;63(4):360-376. doi: 10.1111/jcpp.13543. Epub 2022 Jan 3.
3
Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.氯氮平：COVID-19背景下药物遗传生物标志物、风险及安全性特点的最新综述
Brain Sci. 2020 Nov 11;10(11):840. doi: 10.3390/brainsci10110840.
4
Neutrophil-lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records.跨精神科诊断的中性粒细胞与淋巴细胞比值：使用电子健康记录的横断面研究。
BMJ Open. 2020 Jul 19;10(7):e036859. doi: 10.1136/bmjopen-2020-036859.
5
Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.氯氮平治疗难治性精神分裂症的反应率：系统评价和荟萃分析的数据。
Can J Psychiatry. 2017 Nov;62(11):772-777. doi: 10.1177/0706743717718167. Epub 2017 Jun 28.
6
Can RDoC Help Find Order in Thought Disorder?研究领域标准（RDoC）能否帮助梳理思维紊乱？
Schizophr Bull. 2017 May 1;43(3):503-508. doi: 10.1093/schbul/sbx030.
7
Translating genome-wide association findings into new therapeutics for psychiatry.将全基因组关联研究结果转化为精神科的新疗法。
Nat Neurosci. 2016 Oct 26;19(11):1392-1396. doi: 10.1038/nn.4411.
8
[The Research Domain Criteria (Rdoc), reductionism and clinical psychiatry].[研究领域标准（Rdoc）、还原论与临床精神病学]
Rev Synth. 2016 Dec;137(1-2):117-49. doi: 10.1007/s11873-016-0292-8.
9
Childhood adversity and psychosis: generalised or specific effects?儿童逆境与精神病：普遍还是特定影响？
Epidemiol Psychiatr Sci. 2016 Aug;25(4):349-59. doi: 10.1017/S204579601500044X. Epub 2015 Jul 9.
10
Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice.对精神疾病重叠现象的基因组学见解：对研究和临床实践的启示。
Genome Med. 2014 Apr 28;6(4):29. doi: 10.1186/gm546. eCollection 2014.
本文引用的文献
1
Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project.迈向精神障碍的新治疗方法：美国国立精神卫生研究所研究领域标准项目
Schizophr Bull. 2010 Nov;36(6):1061-2. doi: 10.1093/schbul/sbq108. Epub 2010 Oct 7.
Zotero 插件